|Day Low/High||0.02 / 0.03|
|52 Wk Low/High||3.35 / 10.88|
Company Plans to file 2016 Fourth Quarter and Year End Financial Results by March 30, 2017
Single-Center Retrospective Data Also Demonstrate Therapy Extends Progression-Free Survival by 9 Months
Retrospective Analysis of Outcomes with Investigational Melphalan/HDS and Commercial CHEMOSAT® Projects Median Overall Survival to be 657 Days; 1,207 Days for Responders
Company Accepts Invitation from Cholangiocarcinoma Foundation to Present Initial Signals in ICC
Delcath Systems, Inc. (DCTH) (the "Company"), an interventional oncology company focused on treatments for primary and metastatic liver cancers, today announced the pricing of an underwritten public offering of 425,000...
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on developing safe and effective treatments for primary and metastatic liver cancers, announces that results from two single-institution...
Unprecedented Progression Free and Overall Survival Observed in University Hospital Southampton Retrospective Analysis
Againsttheodds.eu Recognized for High Quality Consumer Health Content
Proceeds expected to fund operations through year-end 2017